Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Comparison of Risk Stratification Models to Predict Recurrence and Survival in Pleuropulmonary Solitary Fibrous Tumor.

Reisenauer JS, Mneimneh W, Jenkins S, Mansfield AS, Aubry MC, Fritchie KJ, Allen MS, Blackmon SH, Cassivi SD, Nichols FC, Wigle DA, Shen KR, Boland JM.

J Thorac Oncol. 2018 Jun 20. pii: S1556-0864(18)30712-3. doi: 10.1016/j.jtho.2018.05.040. [Epub ahead of print]

PMID:
29935303
2.

Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma.

Mansfield AS, Peikert T, Vogelzang NJ, Symanowski JT.

Mayo Clin Proc. 2018 Aug;93(8):1026-1033. doi: 10.1016/j.mayocp.2018.01.032. Epub 2018 May 24.

PMID:
29804728
3.

DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migration.

Alam SK, Astone M, Liu P, Hall SR, Coyle AM, Dankert EN, Hoffman DK, Zhang W, Kuang R, Roden AC, Mansfield AS, Hoeppner LH.

Commun Biol. 2018;1. pii: 43. doi: 10.1038/s42003-018-0050-6. Epub 2018 May 3.

4.

Incidence of major hemorrhage after aggressive image-guided liver mass biopsy in the era of individualized medicine.

Boyum JH, Atwell TD, Wall DJ, Mansfield AS, Kerr SE, Gunderson TM, Rumilla KM, Weisbrod AJ, Kurup AN.

Abdom Radiol (NY). 2018 May 17. doi: 10.1007/s00261-018-1637-6. [Epub ahead of print]

PMID:
29774381
5.

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, Jang JS, Jen J, Li Y, Chanana P, Mansfield AS, Park SS, Markovic SN, Dronca RS, Dong H.

JCI Insight. 2018 Apr 19;3(8). pii: 97828. doi: 10.1172/jci.insight.97828. [Epub ahead of print]

6.

Progress in the Management of Malignant Pleural Mesothelioma in 2017.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T.

J Thorac Oncol. 2018 May;13(5):606-623. doi: 10.1016/j.jtho.2018.02.021. Epub 2018 Mar 8. Review.

PMID:
29524617
7.

Contraction of T cell richness in lung cancer brain metastases.

Mansfield AS, Ren H, Sutor S, Sarangi V, Nair A, Davila J, Elsbernd LR, Udell JB, Dronca RS, Park S, Markovic SN, Sun Z, Halling KC, Nevala WK, Aubry MC, Dong H, Jen J.

Sci Rep. 2018 Feb 1;8(1):2171. doi: 10.1038/s41598-018-20622-8.

8.

Detection and localization of surgically resectable cancers with a multi-analyte blood test.

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N.

Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.

PMID:
29348365
9.

Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma.

Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC.

Oncoimmunology. 2017 Jul 27;6(11):e1356146. doi: 10.1080/2162402X.2017.1356146. eCollection 2017.

10.

Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years.

Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, Leventakos K, Hubbard JM, Mansfield AS, Go RS, Adjei AA.

J Oncol Pract. 2018 Jan;14(1):e1-e10. doi: 10.1200/JOP.2017.025288. Epub 2017 Nov 3.

PMID:
29099678
11.

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011.

Enninga EAL, Moser JC, Weaver AL, Markovic SN, Brewer JD, Leontovich AA, Hieken TJ, Shuster L, Kottschade LA, Olariu A, Mansfield AS, Dronca RS.

Cancer Med. 2017 Oct;6(10):2203-2212. doi: 10.1002/cam4.1152. Epub 2017 Sep 6.

12.

Feasibility and Acceptability of a Dignity Therapy/Life Plan Intervention for Patients With Advanced Cancer.

Dose AM, Hubbard JM, Mansfield AS, McCabe PJ, Krecke CA, Sloan JA.

Oncol Nurs Forum. 2017 Sep 1;44(5):E194-E202. doi: 10.1188/17.ONF.E194-E202.

PMID:
28820511
13.

Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) non-small cell lung cancer.

Breen WG, Merrell KW, Mansfield AS, Wigle DA, Garces YI, Park SS, Olivier KR, Hallemeier CL.

Adv Radiat Oncol. 2016 Dec 21;2(1):12-18. doi: 10.1016/j.adro.2016.12.004. eCollection 2017 Jan-Mar.

14.

FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery.

Arnett AL, Packard AT, Mara K, Mansfield AS, Wigle DA, Haddock MG, Park SS, Olivier KR, Garces YI, Merrell KW.

Pract Radiat Oncol. 2017 Nov - Dec;7(6):e531-e541. doi: 10.1016/j.prro.2017.04.013. Epub 2017 Apr 19.

PMID:
28733185
15.

Pulmonary sarcomatoid carcinoma-a new hope.

Boland JM, Mansfield AS, Roden AC.

Ann Oncol. 2017 Jul 1;28(7):1417-1418. doi: 10.1093/annonc/mdx276. No abstract available.

PMID:
28637281
16.

Management of Multifocal Lung Cancer: Results of a Survey.

Leventakos K, Peikert T, Midthun DE, Molina JR, Blackmon S, Nichols FC, Garces YI, Hallemeier CL, Murphy SJ, Vasmatzis G, Kratz SL, Holland WP, Thomas CF, Mullon JJ, Shen KR, Cassivi SD, Marks RS, Aubry MC, Adjei AA, Yang P, Allen MS, Edell ES, Wigle D, Mansfield AS.

J Thorac Oncol. 2017 Sep;12(9):1398-1402. doi: 10.1016/j.jtho.2017.05.013. Epub 2017 Jun 3.

PMID:
28583587
17.

Towards a Molecular Classification of Pulmonary Sarcomatoid Carcinomas.

Mansfield AS, Roden AC, Boland JM.

J Thorac Oncol. 2017 Jun;12(6):910-912. doi: 10.1016/j.jtho.2017.04.012. No abstract available.

18.

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.

Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR.

Oncotarget. 2017 Apr 18;8(16):27145-27154. doi: 10.18632/oncotarget.16057.

19.

Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.

Fuentes HE, Oramas DM, Paz LH, Casanegra AI, Mansfield AS, Tafur AJ.

Thromb Res. 2017 Jun;154:28-34. doi: 10.1016/j.thromres.2017.03.024. Epub 2017 Apr 1.

PMID:
28402864
20.

Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?

Mansfield AS.

Lung Cancer. 2017 Mar;105:49-51. doi: 10.1016/j.lungcan.2017.01.004. Epub 2017 Jan 9. No abstract available.

PMID:
28089229
21.

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.

Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS.

Clin Cancer Res. 2017 Jul 1;23(13):3277-3284. doi: 10.1158/1078-0432.CCR-16-2299. Epub 2016 Dec 30.

22.

Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: reply.

Mansfield AS, Tafur AJ.

J Thromb Haemost. 2017 Mar;15(3):591-592. doi: 10.1111/jth.13592. Epub 2017 Feb 3. No abstract available.

PMID:
27992093
23.

PS01.12: C11-Choline Positron Emission Tomography and the Detection of Primary Lung Cancers: Topic: Medical Oncology.

Moser J, Cassivi S, Kwon E, Mansfield AS.

J Thorac Oncol. 2016 Nov;11(11S):S276. doi: 10.1016/j.jtho.2016.09.047. Epub 2016 Oct 28. No abstract available.

24.

A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome.

Jatoi A, Grudem ME, Dockter TJ, Block MS, Villasboas JC, Tan A, Deering E, Kasi PM, Mansfield AS, Botero JP, Okuno SH, Smith DR, Fields AP.

Support Care Cancer. 2017 Mar;25(3):833-838. doi: 10.1007/s00520-016-3467-9. Epub 2016 Nov 12.

25.

B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells.

Liu X, Wu X, Cao S, Harrington SM, Yin P, Mansfield AS, Dong H.

Sci Rep. 2016 Nov 8;6:36722. doi: 10.1038/srep36722.

26.

Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.

Mansfield AS, Murphy SJ, Harris FR, Robinson SI, Marks RS, Johnson SH, Smadbeck JB, Halling GC, Yi ES, Wigle D, Vasmatzis G, Jen J.

Ann Oncol. 2016 Nov;27(11):2111-2117. Epub 2016 Oct 14.

27.

BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma.

Dronca RS, Mansfield AS, Park SS, Dong H.

Immunotherapy. 2016 Dec;8(12):1351-1353. doi: 10.2217/imt-2016-0100. Epub 2016 Oct 27. No abstract available.

28.

CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1.

Yin P, Liu X, Mansfield AS, Harrington SM, Li Y, Yan Y, Dong H.

Oncotarget. 2016 Oct 25;7(43):70223-70231. doi: 10.18632/oncotarget.11833.

29.

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.

Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H.

Ann Oncol. 2016 Oct;27(10):1953-8. doi: 10.1093/annonc/mdw289. Epub 2016 Aug 8.

30.

Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.

Leventakos K, Mansfield AS.

BioDrugs. 2016 Oct;30(5):397-405. Review.

PMID:
27411930
31.

c-Met expression and MET amplification in malignant pleural mesothelioma.

Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, Smith CY, Molina JR, Peikert T, Roden AC.

Ann Diagn Pathol. 2016 Aug;23:1-7. doi: 10.1016/j.anndiagpath.2016.04.007. Epub 2016 Apr 30.

PMID:
27402216
32.

Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.

Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P.

J Thromb Haemost. 2016 Sep;14(9):1773-8. doi: 10.1111/jth.13378. Epub 2016 Sep 9.

33.

S768I Mutation in EGFR in Patients with Lung Cancer.

Leventakos K, Kipp BR, Rumilla KM, Winters JL, Yi ES, Mansfield AS.

J Thorac Oncol. 2016 Oct;11(10):1798-801. doi: 10.1016/j.jtho.2016.05.007. Epub 2016 May 20.

34.

88P: Use of brain imaging in the management of patients with lymph node negative multifocal lung cancer.

Leventakos K, Mansfield AS, Blackmon S, Cassivi S, Shen R, Nichols FC, Molina JR, Allen MS, Aubry MC, Wigle D.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S93-4. doi: 10.1016/S1556-0864(16)30201-5. Epub 2016 Apr 15. No abstract available.

35.

The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects.

Mansfield AS, Rudek MA, Vulih D, Smith GL, Harris PJ, Ivy SP; NCI Organ Dysfunction Working Group.

Clin Cancer Res. 2016 Nov 15;22(22):5472-5479. doi: 10.1158/1078-0432.CCR-16-0449. Epub 2016 May 17.

36.

T cell Bim levels reflect responses to anti-PD-1 cancer therapy.

Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H.

JCI Insight. 2016 May 5;1(6). pii: e86014.

37.

Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.

Mansfield AS, Dong H.

Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3.

PMID:
26916808
38.

Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer.

Mansfield AS, Murphy SJ, Peikert T, Yi ES, Vasmatzis G, Wigle DA, Aubry MC.

Clin Cancer Res. 2016 May 1;22(9):2177-82. doi: 10.1158/1078-0432.CCR-15-2246. Epub 2015 Dec 14.

39.

Rapidly Appearing Sclerotic Vertebral Lesions in a Patient With an Infiltrative Mediastinal Mass.

Mansfield AS, White D.

JAMA Oncol. 2016 Feb;2(2):267-8. doi: 10.1001/jamaoncol.2015.4576. No abstract available.

PMID:
26584205
40.

Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials.

Mansfield AS, Tafur AJ, Vulih D, Smith GL, Harris PJ, Ivy SP.

Thromb Res. 2015 Dec;136(6):1169-73. doi: 10.1016/j.thromres.2015.10.024. Epub 2015 Oct 20.

41.

Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.

Tafur AJ, Dale G, Cherry M, Wren JD, Mansfield AS, Comp P, Rathbun S, Stoner JA.

Thromb Res. 2015 Dec;136(6):1120-5. doi: 10.1016/j.thromres.2015.10.004. Epub 2015 Oct 8.

42.

Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma.

Grotz TE, Jakub JW, Mansfield AS, Goldenstein R, Enninga EA, Nevala WK, Leontovich AA, Markovic SN.

Oncoimmunology. 2015 Jun 1;4(8):e1026504. eCollection 2015 Aug.

43.

Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy.

Moser JC, Peikert T, Roden AC, Midthun DE, Mansfield AS.

Ann Am Thorac Soc. 2015 Sep;12(9):1416-7. doi: 10.1513/AnnalsATS.201506-315LE. No abstract available.

PMID:
26372807
44.

Synergy of cancer immunotherapy and radiotherapy.

Mansfield AS, Park SS, Dong H.

Aging (Albany NY). 2015 Mar;7(3):144-5. No abstract available.

45.

Reflections on immune checkpoint inhibition in non-small cell lung cancer.

Leventakos K, Mansfield AS.

Transl Lung Cancer Res. 2014 Dec;3(6):411-3. doi: 10.3978/j.issn.2218-6751.2014.09.09. No abstract available.

46.

Development and external validation of a prognostic nomogram for metastatic uveal melanoma.

Valpione S, Moser JC, Parrozzani R, Bazzi M, Mansfield AS, Mocellin S, Pigozzo J, Midena E, Markovic SN, Aliberti C, Campana LG, Chiarion-Sileni V.

PLoS One. 2015 Mar 17;10(3):e0120181. doi: 10.1371/journal.pone.0120181. eCollection 2015.

47.

PD-1 Restrains Radiotherapy-Induced Abscopal Effect.

Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED.

Cancer Immunol Res. 2015 Jun;3(6):610-9. doi: 10.1158/2326-6066.CIR-14-0138. Epub 2015 Feb 19.

48.

DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers.

Mansfield AS, Wang L, Cunningham JM, Jen J, Kolbert CP, Sun Z, Yang P.

Cancer Genet. 2015 May;208(5):253-60. doi: 10.1016/j.cancergen.2014.12.002. Epub 2014 Dec 31.

49.

Pregnancy-associated plasma protein-A expression in human breast cancer.

Mansfield AS, Visscher DW, Hart SN, Wang C, Goetz MP, Oxvig C, Conover CA.

Growth Horm IGF Res. 2014 Dec;24(6):264-7. doi: 10.1016/j.ghir.2014.10.007.

50.

Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer.

Kourelis TV, Wysokinska EM, Wang Y, Yang P, Mansfield AS, Tafur AJ.

Lung Cancer. 2014 Dec;86(3):358-62. doi: 10.1016/j.lungcan.2014.10.003. Epub 2014 Oct 12.

Supplemental Content

Loading ...
Support Center